Switch theme
Sign up to access all valuation multiples
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
2016
97
Last FY Revenue n/a
LTM EBITDA -$98.0M
$44.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Tenaya Therapeutics has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$98.0M.
In the most recent fiscal year, Tenaya Therapeutics achieved revenue of n/a and an EBITDA of -$107M.
Tenaya Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Tenaya Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$98.0M | XXX | -$107M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$107M | XXX | -$116M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$104M | XXX | -$111M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 31, 2025, Tenaya Therapeutics's stock price is $1.
Tenaya Therapeutics has current market cap of $119M, and EV of $44.2M.
See Tenaya Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $44.2M | $119M | XXX | XXX | XXX | XXX | $-1.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 31, 2025, Tenaya Therapeutics has market cap of $119M and EV of $44.2M.
Tenaya Therapeutics's trades at n/a EV/Revenue multiple, and -0.4x EV/EBITDA.
Equity research analysts estimate Tenaya Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Tenaya Therapeutics has a P/E ratio of -1.1x.
See valuation multiples for Tenaya Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $119M | XXX | $119M | XXX | XXX | XXX |
| EV (current) | $44.2M | XXX | $44.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| EV/EBITDA | -0.5x | XXX | -0.4x | XXX | XXX | XXX |
| EV/EBIT | -0.4x | XXX | -0.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.1x | XXX | -1.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialTenaya Therapeutics's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.2M for the same period.
Tenaya Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Tenaya Therapeutics's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Tenaya Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 1% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Tenaya Therapeutics acquired XXX companies to date.
Last acquisition by Tenaya Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Tenaya Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Tenaya Therapeutics founded? | Tenaya Therapeutics was founded in 2016. |
| Where is Tenaya Therapeutics headquartered? | Tenaya Therapeutics is headquartered in United States of America. |
| How many employees does Tenaya Therapeutics have? | As of today, Tenaya Therapeutics has 97 employees. |
| Who is the CEO of Tenaya Therapeutics? | Tenaya Therapeutics's CEO is Mr. Faraz Ali, M.B.A.. |
| Is Tenaya Therapeutics publicy listed? | Yes, Tenaya Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Tenaya Therapeutics? | Tenaya Therapeutics trades under TNYA ticker. |
| When did Tenaya Therapeutics go public? | Tenaya Therapeutics went public in 2021. |
| Who are competitors of Tenaya Therapeutics? | Similar companies to Tenaya Therapeutics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Tenaya Therapeutics? | Tenaya Therapeutics's current market cap is $119M |
| Is Tenaya Therapeutics profitable? | Yes, Tenaya Therapeutics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Tenaya Therapeutics? | Tenaya Therapeutics's last 12 months EBITDA is -$98.0M. |
| What is the current EV/EBITDA multiple of Tenaya Therapeutics? | Current EBITDA multiple of Tenaya Therapeutics is -0.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
